Alexander Belosludtsev

Mr. Alexander Belosludtsev

Pharmacy, Sechenov University, Moscow, Moskva, Russia
orcid
Looking for co-authors and funding!

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2019 in Russian Medicine
Verified
Journal Article
Open access
VTV. V Tarasov
V. V Tarasov
VCVladimir N. Chubarev
Vladimir N. Chubarev
EZE. S Zykova
E. S Zykova
Alexander BelosludtsevAlexander Belosludtsev
Alexander Belosludtsev
EME. G Mokshanova
E. G Mokshanova
DSD. I Sologova
D. I Sologova
This review is devoted to updating the existing knowledge about pharmacology of the drugs from the group of direct oral anticoagulants (DOACs). Special attention is paid to comparison of the anticoagulant properties of DOACs with traditional (indirect) anticoagulants at various dosage regimens and to study drug interactions of DOACs with drugs from different pharmacological groups. Widely analyzed the side effects associated with errors in the application of DOACs and provided recommendations for their correction, including the using of reversal agents therapy. Based on this, the presented article will be useful to clinicians to familiarize themselves with modern medical strategies based on the use of drugs from the DOACs group for the prevention and treatment of diseases associated with increased blood clotting ability and using of DOACs specific antagonists for treatment overdose of DOACs.

1 January 2023 in Journal of Applied Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
Alexander BelosludtsevAlexander Belosludtsev
Alexander Belosludtsev
TLTatiana Mikhailovna Litvinova
Tatiana Mikhailovna Litvinova
An increase in the number of new drug products (DPs) leads to the growth in the associated information. To improve the efficiency of medical and pharmaceutical care, IT-products are created. In this review, we attempt to systematize innovative domestic IT-solutions (dITSs) for the optimization of remote data management of medicines. We have conducted a systematized search over the past 5 years in accordance with the PRISMA framework. eLibrary, CyberLeninka, and Google were utilized as search engines. 18 out of 312 results met the preset criteria. 23 dITSs were extracted. 18 used big data as the main technology, 2 blockchains, 2 artificial intelligence, and 1 continuous acquisition and lifecycle support/product lifecycle management. The innovations point towards the optimization of drug information in medical organizations (16/23) and pharmacies (6/23). In practice, the dITSs are mainly used as databases (10/23), decision support systems (9/23), and automated analytics (6/23). Specific products are infrequently and not comprehensively assessed in scientific papers. It is more efficient to search them on particular sites dedicated to IT-projects. Today’s reasons for the development of the innovative dITSs to optimize information management within the lifecycle of medicines are a necessity to trace each DP and automate the analysis of related information.